This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The distribution agreement represents an important milestone to expand market access with a highly-respected market leader with an established presence across a broad customer base and a deep knowledge of the clinician need.
''This is a historic day for MolecuLight", says Craig Kennedy, CEO."This partnership further proves our continued commitment to empower clinicians with knowledge allowing them to strengthen their clinical decision making.''
Andy Weymann, MD, Chief Medical Officer at Smith & Nephew says: "The MolecuLight i:X enables healthcare professionals to see what they have never been able to see before, the actual accumulation of fluorescent bacteria in a wound, even when not visible to the naked eye, among other benefits like guiding debridement and wound cleansing, wound measurement, as well as enhance the conversation between the clinician and the patient. MolecuLight i:X enhances clinicians' ability to choose the right therapy, at the right time for their patient1,2.''
''This agreement is a key step for our company and its shareholders and helps us deliver on our pledge to advance wound healing through innovation", says Dr Ralph DaCosta, Founder, Chief Scientific Officer and Board Director. "Our initial customer and patient experience has been excellent. We are confident that Smith & Nephew's longstanding dedication to clinicians and patient wellbeing will help rapidly expand clinical adoption.''
The deviceis currently CE Marked and approved by Health Canada and is available in the European Union and in Canada.The MolecuLight i:X is pending De Novo approval in the USA.
